Bausch + Lomb receives FDA approval for a new IOL on its enVista platform; Nanoscope advances it gene therapy for retinitis pigmentosa; and Orasis completes a major funding round to support the launch of its presbyopia eye drop.  Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices">megaphone.fm/adchoices</a>

Bausch + Lomb receives FDA approval for a new IOL on its enVista platform; Nanoscope advances it gene therapy for retinitis pigmentosa; and Orasis completes a major funding round to support the launch of its presbyopia eye drop. Learn more about your ad choices. Visit megaphone.fm/adchoices

Bausch + Lomb receives FDA approval for a new IOL on its enVista platform; Nanoscope advances it gene therapy for retinitis pigmentosa; and Orasis completes a major funding round to support the launch of its presbyopia eye drop.&nbsp; Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="noopener noreferrer">megaphone.fm/adchoices</a>

B+L Receives FDA Approval for enVista Envy IOL

Eyewire News: The Podcast keeps listeners updated with the latest information in the ophthalmic field, featuring breaking news from press releases, medical journals, vision publications, and other news sources.

News

Business News

Eyewire News: The Podcast keeps listeners updated with the latest information in the ophthalmic field, featuring breaking news from press releases, medical journals, vision publications, and other news sources.

Eyewire News:&nbsp;The Podcast keeps listeners updated with the latest information in the ophthalmic field, featuring breaking news from press releases, medical journals, vision publications, and other news sources.

Share B+L Receives FDA Approval for enVista Envy IOL

Sign up to save your podcasts

B+L Receives FDA Approval for enVista Envy IOL

B+L Receives FDA Approval for enVista Envy IOL